Oppenheimer & Co. Inc. Sells 12,240 Shares of Encompass Health Co. (NYSE:EHC)

Oppenheimer & Co. Inc. lowered its holdings in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 10.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 105,011 shares of the company's stock after selling 12,240 shares during the period. Oppenheimer & Co. Inc. owned about 0.10% of Encompass Health worth $10,148,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. lifted its position in shares of Encompass Health by 387.7% during the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company's stock worth $31,000 after buying an additional 252 shares during the period. V Square Quantitative Management LLC increased its position in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Oakworth Capital Inc. acquired a new position in Encompass Health in the second quarter valued at about $40,000. Benjamin F. Edwards & Company Inc. boosted its stake in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock worth $46,000 after purchasing an additional 198 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Encompass Health during the second quarter worth $58,000. Institutional investors own 97.25% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on EHC shares. KeyCorp increased their price objective on shares of Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a report on Tuesday, October 29th. Royal Bank of Canada lifted their price objective on Encompass Health from $105.00 to $110.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Truist Financial restated a "buy" rating and set a $116.00 price objective (up previously from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. UBS Group upped their price objective on shares of Encompass Health from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Finally, Barclays raised their price objective on Encompass Health from $109.00 to $116.00 and gave the stock an "overweight" rating in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $107.11.

Encompass Health Stock Down 1.5 %

Shares of NYSE:EHC traded down $1.50 during midday trading on Thursday, hitting $101.19. The stock had a trading volume of 540,560 shares, compared to its average volume of 640,558. The company has a market cap of $10.19 billion, a P/E ratio of 24.80, a PEG ratio of 1.36 and a beta of 0.88. Encompass Health Co. has a 12 month low of $63.59 and a 12 month high of $104.55. The business's 50-day simple moving average is $96.08 and its 200-day simple moving average is $90.07. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. Encompass Health's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 EPS. On average, sell-side analysts forecast that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health declared that its board has authorized a stock buyback plan on Wednesday, July 24th that authorizes the company to repurchase $500.00 million in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 5.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Encompass Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd will be paid a $0.17 dividend. This represents a $0.68 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health's dividend payout ratio (DPR) is presently 16.43%.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.